HGS shareholders vow to challenge takeover by GSK
GlaxoSmithKline (GSK) reeled in its long-term drug development partner Human Genome Sciences, with an agreed takeover offer pitched at about $3bn (£1.9bn), though some HGS shareholders immediately said they would challenge the deal.
HGS directors were threatened with a class action lawsuit alleging they breached their duty to shareholders by accepting the GSK offer, which was upped to $14.25 a share – better than the $13 originally tabled. At that price, the deal is double the $7.17 HGS shares were fetching before GSK's bid was disclosed in April.
It has taken the UK drugs giant several months to land its prize, after a battle that began when the US firm rejected its initial offer of $2.6bn in April. As HGS began scrabbling for rival offers to trump GSK, the British company said that it would make its deal hostile.
In the end, the choice facing HGS management was not between GSK and other bidders but between GSK and going it alone.
No other suitors emerged, because of the high cost of unwinding HGS's deep existing relationship with GSK.
Sir Andrew Witty, GSK's chief executive, called it "a mutually beneficial agreement" and the next logical step in the long relationship between the two companies.
Annual cost savings could top $200m by 2015, GSK claimed.
The two companies began working together almost 20 years ago, when GSK paid $125m in 1993 to establish a research partnership.
HGS was one of the first biotech companies to emerge from the early 1990s push to map all of the genes in the human body.
GSK and HGS jointly sell a drug for lupus that they developed together, Benlysta, the first new treatment for the disease to have emerged in half a century.
The drug's sales have so far been sluggish, though analysts remain optimistic and there is also a pipeline of additional and potentially lucrative products.
These include drugs for diabetes and heart disease, in which GSK and HGS share a financial interest.
Thomas Watkins, chief executive of HGS, said that the company has had "a long and productive working relationship with GSK, and together we will be uniquely positioned to achieve the full potential of Benlysta and other products in our pipeline for the benefit of those battling serious disease around the world".
The law firm Levi & Korsinsky last night announced an investigation into potential breaches of fiduciary duty by HGS directors and into whether the company should have held out for a higher price.
The deal is the latest in a busy sector, as drug companies fight for new revenue as traditional moneyspinners come off patent protection.
Last month, Bristol-Myers Squibb said it would pay $5.3bn for diabetes drug maker Amylin.
Malaysia Airlines plane crash exposes alarming flaw in airline security: over one billion flights made last year without stolen-passport check
Swarm of killer bees sting woman 1,000 times
Malaysia Airlines Flight MH370: Oil slicks in South China Sea ‘not from missing jet’, officials say
Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
Oscar Pistorius trial: Athlete repeatedly throws up as court hears 'graphic details' of Reeva Steenkamp's autopsy
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
If you're horrified by a flame-roasted dog, you should be shocked at a hog roast
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
Exclusive: Impact of immigrants on British workers ‘negligible’
Vince Cable: Teachers 'know absolutely nothing' about the world of work
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
- 1 International Women's Day 2014: The shocking statistics that show why it is still so important
- 2 Australian man Rod Sommerville reacts to bite from deadly snake by reaching for cold beer
- 3 North Korea elections: Kim Jong-un wins 100% of the vote
- 4 David Cameron resorts to paying for Facebook fans because not enough people like him
- 5 Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
iJobs Money & Business
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£55000 - £70000 per annum + benefits: Pro-Recruitment Group: In-House Corporat...
£80000 - £100000 per annum + benefits: Pro-Recruitment Group: In-House Opportu...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...